AgomAb Therapeutics N.V. American Depositary Shares

NASDAQ:AGMB

Biotechnology

Healthcare
$5.82 +2.48%

+$0.25 today

Market cap
$286.62M
Beta
2.62
P/E (TTM)
-7.1
EPS (TTM)
-$1.28
52W Low $8.75High $17.45

Volume 0.13M

Average 0.14M

AGMB EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB

EBITDA · Q4 FY2024 · quarter ended Dec 2024

EBITDA of -€11.8M in Q4 FY2024

Q4 FY2024 EBITDA was -€11.8M.

Context

  • EBITDA grew in size in 2 of the last 2 fiscal years.
  • FY2024 was the largest annual figure in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2024
-€11.8M— QoQ
Last fiscal yearDec 2024
-€45.89M-286.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-286.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

EBITDA history

EUR · from the income statement

Latest · FY2024
(45.89M) EUR
Year-over-year change
-286.3%

EBITDA vs competitors

How AGMB compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -286.3% is the lowest of 5, against a peer median of -20.5%.
AGMB Competitors
EBITDA for AGMB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$58.49M USD+176.6%—25.2%
EQEquillium, Inc.LTM Mar 2026-$18.95M USD-40.5%——
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024-€45.89M EUR-286.3%——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$70.61M USD-31.5%—843.9%
ALMSAlumis Inc. Common StockLTM Jun 2026-$442.87M USD-9.5%—5986.3%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding AGMB) —-20.5%—843.9%

Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
Revenue000
Cost of Revenue000
Gross Profit000
Gross Margin———
Research & Development19.42M26.31M39.31M
Selling, General & Admin4.49M6M9.82M
Operating Expenses22.63M31.19M48.02M
Depreciation & Amortization23K99K311K
EBITDA(10.74M)(11.88M)(45.89M)
EBITDA Margin———
Operating Income(22.63M)(31.19M)(48.02M)
Operating Margin———
Interest Income71K245K1.22M
Interest Expense45K31K67K
Other Income / Expenses11.83M19.18M1.76M
Income Before Tax(10.81M)(12.01M)(46.26M)
Pre-Tax Margin———
Income Tax Expense(2.66M)(619K)4K
Net Income(8.14M)(11.39M)(46.27M)
Net Margin———
EPS (Basic)(0.22)(0.31)(1.26)
EPS (Diluted)(0.22)(0.31)(1.26)
Weighted Avg Shares36.24M36.24M36.24M
Weighted Avg Shares (Diluted)36.24M36.24M36.24M

AgomAb Therapeutics N.V. American Depositary Shares

NASDAQ:AGMB

Intrinsic Alpha fair value

Locked

Current Price

$5.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.